Bristol-Myers Squibb (BMS) announced that it has acquired privately held drugmaker Flexus Bioscience Inc. for up to $1.25 billion, gaining control of an investigational immunotherapy. The companies said that they have signed a definitive agreement, under which BMS will acquire all of the outstanding capital stock of Flexus, a company …